Cerebral Ischemic Reperfusion Injuries (CIRI)
Wei-jian Jiang,Wengui Yu,Y. Qu,Zhongsong Shi,B. Luo,John H. Zhang
DOI: https://doi.org/10.1007/978-3-319-90194-7
2018-01-01
Abstract:Stroke is one of the leading causes of death, and acute ischemic stroke (AIS) is the most common form. Tissue plasminogen activator (tPA) is the only FDA-approved drug for recanalization in AIS with narrow therapeutic window. In this chapter, we will discuss the activation of gelatinases (MMP-2/9), one of the major mediators in cerebral ischemia and reperfusion injury (CIRI) with exogenous tPA in AIS. First, we briefly overview the structure of microvascular beds and the homeostasis of neurovascular unit associated with the extracellular matrix (ECM). Then we review the gelatinase-mediated degradation of ECM and the impairment of microvascular beds in AIS. Moreover, we discuss the self-perpetuS. Chen · H. Song Interdisciplinary Neuroscience Program, University of Missouri School of Medicine, Columbia, MO, USA Department of Pathology and Anatomical Sciences, University of Missouri School of Medicine, Columbia, MO, USA J. Cui · Z. Gu (*) Department of Pathology and Anatomical Sciences, University of Missouri School of Medicine, Columbia, MO, USA Harry S. Truman Memorial Veterans’ Hospital Research Service, Columbia, MO, USA e-mail: guze@health.missouri.edu J. I. Shenker Department of Neurology, University of Missouri School of Medicine, Columbia, MO, USA Y. Chen · H. Feng Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China G. Y. Sun Department of Biochemistry, University of Missouri School of Medicine, Columbia, MO, USA Department of Pathology and Anatomical Sciences, University of Missouri School of Medicine, Columbia, MO, USA